A Phase 1/2 study of NS-050/NCNP-03, an investigational exon 50 skipping therapy, in boys with Duchenne muscular dystrophy (Meteor50): Trial design


Topic:

Clinical Trials

Poster Number: 20 S

Author(s):

Bassem Morcos, MD, NS Pharma, Inc., Paramus, NJ, USA, Hirofumi Komaki, MD, PhD, Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, Yoshitsugu Aoki, MD, PhD, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Japan, Eric Hoffman, PhD, AGADA Biosciences, Inc., Mai Watanabe, NS Pharma, Michael Tansey, MS, NS Pharma, Inc., Teppei Hatakeyama, Nippon Shinyaku CO., LTD., Japan, He Zhang, MD, PhD, Nippon Shinyaku CO., LTD., Japan, Tomoyuki Nakagawa, Nippon Shinyaku CO., LTD., Japan, Paula R Clemens, MD, University of Pittsburgh

Background: Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin gene, leading to loss of functional dystrophin protein. Exon skipping therapies aim to restore the dystrophin reading frame by modifying pre-mRNA splicing, enabling production of internally truncated but functional dystrophin. Approximately 4% of individuals with DMD are amenable to exon 50 skipping. NS 050/NCNP 03 is an antisense oligonucleotide designed for patients with mutations suitable for exon 50 skipping. This abstract summarizes the design of a first-in-human Phase 1/2 study evaluating NS 050/NCNP 03 in ambulatory boys with DMD.

Methods: This multicenter Phase 1/2 study (NCT06053814) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of NS 050/NCNP 03. Eligible participants are males aged ≥4 to <15 years with a confirmed DMD gene mutation amenable to exon 50 skipping. Part 1 is a randomized, double blind, placebo-controlled dose escalation phase in which nine participants will receive once weekly intravenous NS 050/NCNP 03 or placebo for two weeks at each dose level. Primary endpoints include safety, tolerability, and pharmacokinetics. Part 2 will enroll an additional 11 participants (total N = 20), all receiving the maximum tolerated dose identified in Part 1 once weekly for 24 weeks. The primary endpoint for Part 2 is dystrophin protein expression in skeletal muscle after 24 weeks. Secondary endpoints include safety, tolerability, dystrophin mRNA induction, and changes in strength and functional mobility compared with a group-matched natural history cohort. Conclusion: This Phase 1/2 trial is the first clinical evaluation of NS 050/NCNP 03 and is designed to characterize safety, pharmacokinetics, pharmacodynamics, and early efficacy signals to support further development.